Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Receivables (2016 - 2026)

Avanos Medical's Receivables history spans 13 years, with the latest figure at $108.0 million for Q4 2025.

  • On a quarterly basis, Receivables fell 18.67% to $108.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $108.0 million, a 18.67% decrease, with the full-year FY2025 number at $108.0 million, down 18.67% from a year prior.
  • Receivables hit $108.0 million in Q4 2025 for Avanos Medical, down from $116.0 million in the prior quarter.
  • Over the last five years, Receivables for AVNS hit a ceiling of $167.9 million in Q4 2022 and a floor of $108.0 million in Q4 2025.
  • Historically, Receivables has averaged $132.0 million across 5 years, with a median of $131.6 million in 2024.
  • Biggest five-year swings in Receivables: tumbled 33.46% in 2021 and later skyrocketed 47.58% in 2022.
  • Tracing AVNS's Receivables over 5 years: stood at $131.2 million in 2021, then increased by 27.97% to $167.9 million in 2022, then dropped by 14.95% to $142.8 million in 2023, then dropped by 7.0% to $132.8 million in 2024, then dropped by 18.67% to $108.0 million in 2025.
  • Business Quant data shows Receivables for AVNS at $108.0 million in Q4 2025, $116.0 million in Q3 2025, and $110.2 million in Q2 2025.